Collectively, our data suggest that dual blockade of ER and PRMT5 can effectively suppress tumor growth of ER+/RB-deficient breast cancer, thus providing the basis to testing this novel therapeutic combination in patients with this refractory breast cancer subtype. Here, ESR1 is linked to breast carcinoma.